⌕
AMGEN · AMGN · Nasdaq
Tenet 47 · Mixed
Compare
$457.93−0.95%At closeTenet 47 · Mixed
$457.93−4.39 (−0.95%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
$456.90−1.03 (−0.22%)
After hours: Nov 17, 2026, 6:19 PM ET

AMGEN (AMGN) Stock

AMGEN (AMGN) closed at $457.93 on Nov 17, 2026; its Tenet Score is 47 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Close
$457.93
Nov 17, 2026
Market cap
$250.1B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
26.9×
TTM through Sep 30, 2026 · as of close, Nov 16, 2026
Dividend yield
2.15%
past year's regular dividends ÷ price · as of close, Nov 16, 2026
52-week range
312.38 – 483.99
low → high · as of close, Nov 16, 2026
Tenet Score
47/100
Mixed · 340 Healthcare peers

Industry: Drugs

AMGEN Inc. scores 47/100. Mixed. Strongest on quality, financial health is the soft spot, trading at 27× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
47/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
44
Quality
70
Health
24
Growth
51

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueDQualityBHealthFGrowthCMomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
17.4×
Sep 30, 2026 balance sheet
P/S
6.4×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
78%
TTM through Sep 30, 2026
Operating margin
24.7%
fiscal 2025, before interest and tax
Net margin
24.1%
TTM through Sep 30, 2026
Current ratio
1.48
Sep 30, 2026 balance sheet
Net debt / EBITDA
2.4×
TTM through Sep 30, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About AMGEN Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 497 US ETFs · top wrappers by weightSee all ETFs holding AMGN →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

CompanyTenet ScoreMarket cap
Abbvie IncABBV42$520.7B
Merck & Co IncMRK41$356.1B
Novartis AGNVS55$305.7B
Gilead Sciences, Inc.GILD38$207.9B
Novo NordiskNVO62$185.7B
Pfizer Inc.PFE50$164.5B
Vertex Pharmaceuticals, Inc.VRTX55$136.4B
Bristol-Myers Squibb Co.BMY51$128.6B
GSK PlcGSK51$108.8B
Regeneron Pharmaceuticals, Inc.REGN64$98.5B

Compare AMGEN with

What sector and industry is AMGEN in?

AMGEN is in the Healthcare sector and the Drugs industry.

What is AMGEN's Tenet Score?

AMGEN's Tenet Score is 47 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.